Thromboembolic events after Ad.26.COV2.S COVID-19 vaccine: Reports to the Vaccine Adverse Event Reporting System

Woo, EJ; Mba-Jonas, A; Thomas, A; Baer, B; Day, B; Kim, Y; Gomez-Lorenzo, M; Nair, N

Woo, EJ (通讯作者)，US FDA, Off Biostat & Pharmacovigilance, Ctr Biol Evaluat & Res, Silver Spring, MD 20903 USA.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022; 31 (11): 1174

Abstract

Purpose: The Food and Drug Administration (FDA) has identified a potential safety concern for thromboembolic events (TEEs) after Ad.26.COV2.S COVID-19......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索